Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Normalization of defective monocyte chemotaxis during chemotherapy in patients with small cell anaplastic carcinoma of the lung

Summary

Monocyte chemotactic responsiveness (MCR) in 14 patients with small cell anaplastic bronchogenic carcinoma was depressed before treatment compared with the MCR in 28 normal controls (P=0.00004). MCR was subsequently monitored during combination chemotherapy and after 6 months the MCR had become normalized compared with pretreatment values (P=0.00006).

In addition, chemotactic factor inhibitor (CFI) activity in plasma was measured before treatment and after 6 months. When incubated with plasma before treatment casein had 62% of normal activity and when incubated with plasma after chemotherapy, 81% of normal activity (P=0.0009). CFI activity decreased by greater amounts in patients in complete remission than in patients in partial remission or in non-responders (P=0.01). This study supports the concept that cancer patients have depressed monocyte function. Chemotherapy seems to enhance monocyte chemotaxis in vitro and to decrease CFI activity in plasma.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Boetcher DA, Leonard ES (1974) Abnormal monocyte chemotactic response in cancer patients. J Natl Cancer Inst 52:1091

  2. 2.

    Böyum AJ (1969) Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 21: Suppl 97

  3. 3.

    Brosman S (1976) Alterations of monocyte chemotaxis in patients with genitourinary carcinoma. In: Crispen RG (ed) Neoplasm immunity: Mechanisms. ITR, Chicago, p 149

  4. 4.

    Brozna JP, Ward PA (1975) Antileukotactic properties of tumor cells. J Clin Invest 56:616

  5. 5.

    Hansen HH, Dombernowsky P, Hansen M, Hirsch F (1978) Chemotherapy of advanced small-cell anaplastic carcinoma. Superiority of a four-drug combination to a three-drug combination. Ann Intern Med 89:177

  6. 6.

    Israël L, Samak R, Eedelstein R (1980) Defective monocyte killing in cancer patients. Lancet II:1311

  7. 7.

    Journey LS, Amos DB (1962) An electron microscope study of histiocyte response to ascites tumor homografts. Cancer Res 26:998

  8. 8.

    Kjeldsberg CR, Pay GD (1978) A qualitative and quantitative study of monocytes in patients with malignant solid tumors. Cancer 41:2236

  9. 9.

    Kleinerman ES, Zwelling LA, Muchmore AW (1980) Enhancement of naturally occurring human spontaneous monocyte-mediated cytotoxicity by cis-diamminedichloroplatinum (II). Cancer Res 40:3099

  10. 10.

    Kleinerman ES, Houser D, Young RC, Bull J, Zwelling LA, Barlock A, Decker JM, Muchmore AW (1980) Defective monocyte killing in patients with malignancies and restoration of function during chemotherapy. Lancet II:1102

  11. 11.

    Kreyberg L (1967) Histological typing of lung tumors. World Health Organization, Geneva

  12. 12.

    Nielsen H, Bennedsen J, Larsen SO, Dombernowsky P, Viskum K (1982) A quantitative and qualitative study of blood monocytes in patients with bronchogenic carcinoma. Cancer Immunol Immunother 13:93–97

  13. 13.

    Pike MC, Snyderman R (1976) Depression of macrophage function by a factor produced by neoplasms: A mechanism for abrogation of immune surveillance. J Immunol 117:1243

  14. 14.

    Rinehart JJ, Lange P, Gormus BJ, Kaplan ME (1978) Human monocyte-induced tumor cell cytotoxicity. Blood 52:211

  15. 15.

    Rubin RH, Cosimi AB, Goetzl EJ (1976) Defective human mononuclear leucocyte chemotaxis as an index of host resistance to malignant melanoma. Clin Immunol Immunopathol 6:376

  16. 16.

    Snyderman R, Seigler HF, Meadows L (1977) Abnormalities of monocyte chemotaxis in patients with melanoma: Effect of immunotherapy and tumor removal. J Natl Cancer Inst 58:37

  17. 17.

    Snyderman R, Meadows L, Holder W, Wells S (1978) Abnormal monocyte chemotaxis in patients with breast cancer: Evidence for a tumor-mediated effect. J Natl Cancer Inst 60:737

  18. 18.

    Ward PA, Berenberg SL (1974) Defective regulation of inflammatory mediators in Hodgkin's disease: supernormal levels of chemotactic-factor inactivator. N Engl J Med 290:76

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Nielsen, H., Bennedsen, J. & Dombernowsky, P. Normalization of defective monocyte chemotaxis during chemotherapy in patients with small cell anaplastic carcinoma of the lung. Cancer Immunol Immunother 14, 13–15 (1982). https://doi.org/10.1007/BF00199426

Download citation

Keywords

  • Carcinoma
  • Cancer Patient
  • Cancer Research
  • Normal Control
  • Complete Remission